

Implantable cardioverter defibrillators for primary prevention of death in left ventricular dysfunction with and without ischaemic heart disease: a meta-analysis of 8567 patients in the 11 trials

Matthew J. Shun-Shin, Sean L. Zheng, Graham D. Cole, James P. Howard, Zachary I. Whinnett*, and Darrel P. Francis

Imperial College London, National Heart and Lung Institute, Hammersmith Hospital Campus, B Block, 2nd floor, NHLI - Cardiovascular Science, Du Cane Road, W12 0NN London, UK

Received 7 November 2016; revised 21 November 2016; editorial decision 11 January 2017; accepted 13 January 2017; online publish-ahead-of-print 21 February 2017

See page 1747 for the editorial comment on this article (doi: 10.1093/eurheartj/ehx096)

Aims

Primary prevention implantable cardioverter defibrillators (ICDs) are established therapy for reducing mortality in patients with left ventricular systolic dysfunction and ischaemic heart disease (IHD). However, their efficacy in patients without IHD has been controversial. We undertook a meta-analysis of the totality of the evidence.

Methods and results

We systematically identified all RCTs comparing ICD vs. no ICD in primary prevention. Eligible RCTs were those that recruited patients with left ventricular dysfunction, reported all-cause mortality, and presented their results stratified by the presence of IHD (or recruited only those with or without). Our primary endpoint was all-cause mortality. We identified 11 studies enrolling 8567 participants with left ventricular dysfunction, including 3128 patients without IHD and 5439 patients with IHD. In patients without IHD, ICD therapy reduced mortality by 24% (HR 0.76, 95% CI 0.64 to 0.90, $P=0.001$). In patients with IHD, ICD implantation (at a dedicated procedure), also reduced mortality by 24% (HR 0.76, 95% CI 0.60 to 0.96, $P=0.02$).

Conclusions

Until now, it has never been explicitly stated that the patients without IHD in COMPANION showed significant survival benefit from adding ICD therapy (to a background of CRT). Even before DANISH, meta-analysis of patients without ischaemic heart disease already showed reduced mortality. DANISH is consistent with these data. With a significant 24% mortality reduction in both aetiologies, it may no longer be necessary to distinguish between them when deciding on primary prevention ICD implantation.

Keywords

Implantable cardiac defibrillators • Meta-analysis • Ischaemic heart disease • Cardiomyopathy • Non-ischaemic • Heart failure

Introduction

Implantable cardiac defibrillators (ICD) are established as preventing death in patients with left ventricular dysfunction and

ischaemic heart disease (IHD).¹ In patients without IHD, however, ICDs are already considered controversial,² and recent trial data have been interpreted as indicating that they are not beneficial.³

* Corresponding author. Tel: +44 207 594 5735, Email: z.whinnett@imperial.ac.uk

© The Author 2017. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

We set out to analyse the totality of RCT data of ICD vs. no ICD therapy in primary prevention of mortality in patients with left ventricular dysfunction.

Methods

Eligibility and search strategy

We identified all reports of studies of the use of ICD therapy against no ICD therapy for primary prevention in patients with left ventricular systolic dysfunction, in which outcome data was available stratified by the presence of IHD, or recruited only one of these two groups. We included cardiac resynchronization therapy (CRT) RCTs that included a defibrillator arm (CRT-D) and a cardiac resynchronization pacing only arm (CRT-P). We did not include comparisons between CRT-D and no device.

Pubmed (1st January 1946 to 18th December 2016), EMBASE (1st January 1974 to 18th December 2016), and the Cochrane Central register for randomized controlled trials using the search strategy detailed in Supplementary material online, Appendix S1. Only articles in English were considered. Reference lists and relevant systematic reviews were hand-searched for additional publications. No published protocol exists for this systematic review and meta-analysis.

Data abstraction

Data was independently extracted by two authors (SZ, MJS), including year, participants, intervention, and outcomes. Disagreements were resolved by discussion with a third reviewer (DPF). The risk of bias was independently assessed by two authors (SZ, MJS). We sought data on the primary outcome measure of all-cause mortality. Secondary outcome measures included cardiovascular mortality and sudden cardiac death. We also collected data on specific ICD associated complications including inappropriate shocks and device-related infections. We abstracted reported hazard ratios with confidence intervals, and appropriately transformed them for meta-analysis. If hazard ratios or their confidence intervals were not available, but Kaplan-Meier plots were available, we extracted the underlying data using Digitizer⁴ and converted to hazard ratios and their standard errors.⁵ If a trial⁶ randomized patients to control, CRT-Defibrillator, and CRT-Pacemaker; and only presented data stratified by aetiology for the CRT-Defibrillator vs. control, and CRT-Pacemaker vs. control comparisons; the effect of the defibrillator component was determined by indirect comparison of the CRT-Defibrillator vs. the CRT-Pacemaker arms. The steps used to calculate the hazard ratio effect of the defibrillator component, and derive its confidence interval, for the groups with and without IHD separately, are shown in Supplementary material online, Appendix S2, and are based on formulae from Tierney *et al.*⁷

If hazard ratio data were unavailable⁸ we extracted risk ratios.

Risk of bias assessment

We used the Cochrane Risk of Bias Tool⁹ to assess all trials for bias across six domains (selection, performance, detection, attrition, reporting, and other).

Data analysis

Where appropriate, we quantitatively synthesised the extracted hazard ratios and risk ratios using a random-effects meta-analysis with the Restricted Maximum Likelihood (REML) estimator. We calculated the annualized mortality rate across for each aetiology by dividing the overall mortality rate in the control group by the mean follow-up time, and

weighting by study size. The I^2 statistic was used to measure heterogeneity of trial results.¹⁰ We carried out a sensitivity analysis for patients without IHD by omitting each of the trials in turn and repeating the meta-analysis. Publication bias was graphically assessed using Funnel plots, with Egger's test for asymmetry.¹¹ Data were analysed using "R",¹² and the package "metafor".¹³ The PRISMA checklist is included as Supplementary Data.¹⁴

Results

The primary search yielded 2698 records, which were processed as shown in the study flow chart (Figure 1). Full-text was independently reviewed for 219 articles and 11 trials of ICD therapy for primary prevention were included. Three additional articles reported secondary outcomes for included trials.^{15–17} Two trials enrolled patients with left ventricular dysfunction regardless of aetiology,^{6,18} four trials enrolled patients exclusively without IHD,^{8,19–21} three exclusively with chronic IHD,^{22–24} and two trials exclusively after an acute myocardial infarction.^{25,26} One trial⁸ used amiodarone as the comparator, all other trials continued prescribed therapy.

Three trials^{27–29} were excluded as they recruited patients resuscitated from an arrhythmic cardiac arrest, with an ICD inserted as secondary prevention. One trial³⁰ was excluded as, whilst it was a randomized controlled trial, allocation to insertion of an ICD was not randomized.

A total of 8567 participants were enrolled (4371 ICD therapy, 4196 control), 3128 without IHD and 5439 with IHD (Table 1, study characteristics).

Risk of bias assessment

Trial quality was assessed using Cochrane risk of bias tool (Table 2). There was no effective blinding of therapy in any of the trials. We assessed our primary end-point of all-cause mortality as having a low risk of bias. End-points requiring clinical judgement, such as sudden cardiac death and cardiovascular death, are at risk of bias if assessors are not blinded. Only five^{6,8,20,21,26} of the eleven trials reported on procedures to blind end-point assessment. Secondary outcomes were poorly reported, and often used different statistical measures to the primary outcome.

Populations studied

Across the 11 trials, the mean age was 63.1 years. Most trials enrolled patients with an EF \leq 35%; two trials enrolled those with an EF \leq 30%,^{19,23} and one enrolled those with an LVEF \leq 40%.²⁶

All trials included patients with NYHA Class III symptoms. In 5 trials only patients who were NYHA Class II and III were included. Three trials included patients with NYHA Class IV symptoms, but these accounted for only a small proportion of patients (14%, 4%, 1%). One trial⁶ did not recruit NYHA Class II patients. 5 trials^{8,21,23,25,26} included NYHA Class I patients.

The electrophysiology inclusion criteria varied between the trials with 6 trials enrolling based on previous NSVT or ectopics, and 5 having no specific electrophysiological inclusion criteria.

In one trial,²² ICDs were placed with epicardial leads during coronary artery bypass grafting (CABG) surgery. In one trial,²⁴ 47% were placed with epicardial leads and 53% placed with transvenous leads.




Figure 1 Study flow chart.

In all other studies transvenous leads were used. The studies enrolling patients with chronic IHD recruited patients at least 3 weeks after previous MI; those enrolling patients with acute MI within 31 days²⁶ or 40 days of an MI.²⁵ Baseline characteristics, inclusion, and exclusion criteria are detailed in Table 1.

Effect on all-cause mortality

Left ventricular dysfunction without ischaemic heart disease

Across the 3128 patients without ischaemic heart disease, there was a significant reduction in all-cause mortality with minor heterogeneity (HR 0.76, 95% CI 0.64 to 0.90, $P=0.001$, $I^2=3\%$, Figure 2). The annualized mortality rate in control patients was 5.4%.

A sensitivity analyses, carried out by omitting each of the trials in turn, in each case shows a statistically significant consensus reduction in mortality (see Supplementary material online, Appendix S4). A funnel plot did not show any significant asymmetry (Egger's test $P=0.5$, Supplementary material online, Appendix S5).

Left ventricular dysfunction with ischaemic heart disease

Across the 3867 patients in all trials of primary prevention ICD therapy with ischaemic heart disease and no recent MI, there was a non-significant reduction in all-cause mortality (pooled HR 0.81, 95% CI 0.65 to 1.03, $P=0.08$, Figure 3A). However, there was substantial

heterogeneity ($I^2=62\%$). One trial²² was unique in inserting the ICD at the time of CABG surgery. There was a 16% higher infection rate in the ICD group, with 4.3% requiring removal. Current practice is to minimize infection risk by implanting the cardiac device separately from any open surgery. Running the analysis for the trials that tested this approach showed a significant reduction in mortality (HR 0.76, 95% CI 0.60 to 0.96, $P=0.02$, $I^2=52\%$, Figure 3B). The annualized mortality rate in the control patients was 11.3%. A funnel plot did not show any significant asymmetry (Egger's test $P=0.2$, Supplementary material online, Appendix S5).

Left ventricular dysfunction with acute myocardial infarction

In the 2 trials that enrolled 1572 patients after an acute MI, ICD therapy did not cause a significant reduction in mortality (HR 1.05, 95% CI 0.86 to 1.30, $P=0.6$, $I^2=0\%$, Figure 4). The annualized event rate in the control patients was 7.6%. Supplementary material online, Appendix S5 contains the funnel plot.

Effect on secondary outcomes

Secondary outcomes were inconsistently reported with not all trials presenting data. Some data were presented as raw counts from which risk ratios could be derived, and some as hazard ratios. ICD therapy was consistently associated with a statistically significant

Table 1 Study characteristics

Trial	CABG-Patch	MADIT I	MADIT II	CAT	AMIOVIRT	DEFINITE	DINAMIT	COMPANION	SCD-HeFT	IRIS	DANISH
Year	1996	1996	2002	2002	2003	2004	2004	2004	2005	2009	2016
Author	Bigger	Moss	Moss	Bänsch	Strickberger	Kadish	Hohnloser	Bristow	Bardy	Steinbeck	Kober
Intervention	ICD	ICD	ICD	ICD	ICD	ICD	ICD	CRT-D	ICD	ICD	ICD
Control	SMT	SMT	SMT	SMT	Amiodarone	SMT	SMT	CRT-P	SMT	SMT	SMT
LVEF cut-off	<36%	<35%	<30%	<30%	<35%	<36%	<35%	<35%	<35%	<40%	<35%
Randomized (N)	900	196	1232	104	103	458	674	1520	1676	898	1116
Without IHD	–	–	–	100% (n = 104)	100% (n = 103)	100% (n = 458)	–	44% (n = 669)	47% (n = 792)	–	100% (n = 1116)
With IHD	100% (n = 900)	100% (n = 196)	100% (n = 1232)	–	–	–	100% (n = 674)	56% (n = 851)	53% (n = 884)	100% (n = 898)	–
ICD group N	446	95	742	50	51	229	332	595	829	445	556
Follow-up (months)	32	27	20	66	24	29	30	15.8	45.5	37	67.6
Primary outcome	ACM	ACM	ACM	ACM	ACM	ACM	ACM	ACM and hospitalization	ACM	ACM	ACM
Inclusion criteria	Undergoing CABG, abnormal ECG	MI, NSVT, NYHA 1-3	MI, NYHA 1-3	Recent DCM diagnosis, NYHA 2-3	NYHA 1-3, asymptomatic	Symptomatic DCM, ambient arrhythmias	Recent MI	NYHA 3-4, recent HF hospitalization	NYHA class 2-3, QMT	Recent MI	NYHA 2-4, raised NT-proBNP
Exclusion criteria	Sustained VT or VF	Cardiac arrest, syncope, VT, NYHA 1-3	MI within 1 month	Valvular, HCM or restrictive, prior MI	Syncope	NYHA 4, familial cardiomyopathy	NYHA 4	–	–	NYHA 4, ventricular arrhythmia before or ≥ 48 h after	–
EP inclusion criteria	QRS ≥ 114 or other signal averaged ECG abnormalities	NSVT (3-30 beats at rate >120)	VE	Excluded VT, VF, symptomatic brady	Asymptomatic NSVT (>3 beats, HR > 100, lasting <30s)	NSVT (3-15 beats, HR < 120) or < 10 PVC/h	None	QRS ≥ 120 ms, PR ≥ 150 ms, SR	None	HR ≥ 90, or NSVT (≥ 3 beats, HR ≥ 150)	None
IHD definition	Undergoing CABG	Q wave or cardiac enzyme positive MI	Q wave, cardiac enzymes, fixed defect nuclear scan, akinesis	No stenosis > 70% at coronary angiography	Absent CAD or out of proportion to CAD	Clinically significant CAD on angio or negative stress imaging	Recent MI	Not specified	≥ 75% narrowing of major artery, prior MI	STEMI or NSTEMI	No significant CAD on invasive or CT angiogram, or normal MPS. Allowed 2 stenosed coronaries if felt not significant.
Time after MI	–	>3 weeks	>1 month	NA	NA	NA	6-40 days	–	–	5-31 days	NA
ICD type	Epicardial	Epicardial 47% Transvenous 53%	Transvenous	Transvenous	Transvenous	Transvenous	Transvenous	Transvenous	Transvenous	Transvenous	Transvenous
CRT implantation permitted	–	–	–	–	–	Yes	–	Yes	–	–	Yes
Age (meantstd)	64±9	63	65 ± 10	52 ± 11	59 ± 12	58 (range 20-84)	62 ± 11	67	60	63 ± 11	64
Male	84%	92%	85%	80%	70%	71%	76%	68%	77%	77%	73%
ACEI/ARB	54%	62%	70%	96%	86%	97%	95%	89%	96%	82%	97%
BB	21%	23%	70%	4%	52%	85%	87%	68%	69%	98%	92%
CRT	0%	0%	NR	NR	NR	2%	NR	100%	NR	NR	58%
LVEF	27% (Mean)	26% (Mean)	23% (Mean)	24% (Mean)	23% (Mean)	21% (Mean)	28% (Mean)	21% (Median)	25% (Median)	35% (Mean)	25% (Median)

Continued

Table 1 Continued

Trial	CABG-Patch	MADIT I	MADIT II	CAT	AMIOVIRT	DEFINITE	DINAMIT	COMPANION	SCD-HeFT	IRIS	DANISH
QRS width (ms)	NR (73% >100ms)	NR	NR (51% > 120ms)	108	NR	115	106	160	NR	NR	CRT 160No CRT 108
QRS normal	NR	NR	49%	64%	NR	NR	NR	NR	NR	NR	NR
QRS abnormal	LB88 11%	LB88 8%	LB88 19%	LB88 30%	LB88 48%	LB88 20%	NR	LB88 71%	NR	LB88 8%	CRT LB88 94%, RB88
			RB88 8%	RB88 1%	RB88 12%	RB88 3%		RB88 11%			3% No CRT LB88
NYHA I			37%	0%	16%	22%	13%	0%	Excluded	Recruited	17%, RB88 5%
NYHA II	73% (II and III)	65% (II and III)	35%	65%	64%	57%	60%	0%	Recruited	Recruited	0%
NYHA III			24%	35%	20%	21%	27%	86%	Recruited	Recruited	53%
NYHA IV			4%	0%	0%	0%	0%	14%	Excluded	Excluded	45%
Hypertension	NR	42%	53%	NR	63%	NR	46%	NR	56%	66%	1%
Diabetes	38%	6% (IDDM)	36%	NR	34%	23%	30%	NR	31%	34%	31%
Atrial fibrillation	NR	NR	NR	NR	NR	25%	NR	NR	15%	14%	19%

ICD, implantable cardioverter defibrillator; CRT-D/P, cardiac resynchronization therapy-defibrillator/pacemaker; SMT, standard medical therapy; ACM, all-cause mortality; MI, myocardial infarction; NSVT, non-sustained ventricular tachycardia; NYHA, New York Heart Association Functional Classification; DCM, dilated cardiomyopathy; HF, heart failure; OMT, optimal medical therapy; VF, ventricular tachycardia; VT, ventricular fibrillation; CAD, coronary artery disease; MPS, myocardial perfusion scintigraphy; CABG, coronary artery bypass graft; NR, not applicable.

reduction in hazard ratio and risk ratios for all three groups (without IHD, with IHD, and acute MI) for sudden cardiac death (without IHD HR 0.4 RR 0.29; with IHD HR 0.38 RR 0.41; acute MI HR 0.49, RR 0.57, Supplementary material online, Appendix S3).

Discussion

Based on high-quality data from RCTs, this meta-analysis finds that primary prevention ICDs reduce all-cause mortality in patients with left ventricular dysfunction both with and without IHD. No benefit from ICDs is seen in the setting of acute myocardial infarction. These findings are consistent with the current ESC guideline recommended management.^{31,32}

Patients without ischaemic heart disease

There has been controversy over the utility of ICDs in patients without IHD. Many of the published guidelines make a distinction between the aetiologies with respect to the level of evidence on which their recommendations are made. The 2015 European Society of Cardiology (ESC) ventricular arrhythmia guidelines,³¹ and the 2016 ESC heart failure guideline³² give ICDs for primary prevention a 1A recommendation for an ischaemic aetiology, and 1B for a non-ischaemic aetiology. Indeed, this uncertainty was the stimulus for conducting the recent DANISH study. Subsequent commentary³ has added to the uncertainty.

Part of this uncertainty may have arisen as mortality rate in patients without IHD is lower than those with IHD (5.4%/year vs. 11.3%/year, respectively), and consequently the confidence intervals are wider for individual trials.

However, all the point estimates lie in the range 0.55 to 0.87, and the trials showed minimal heterogeneity ($I^2 = 3\%$). The group without IHD in COMPANION was, even on its own, statistically significant for a reduction of all-cause mortality with ICD (see Supplementary material online, Appendix S2), although this was not the chosen central message of the COMPANION primary publication.

Our meta-analysis confirms a statistically significant reduction in all-cause mortality by primary prevention ICD in patients without IHD. Whilst only one trial was individually significant, the point estimates from all 6 trials were in the same direction, suggestive of benefit. Furthermore, even omitting both COMPANION and the recent DANISH trial from the meta-analysis still produces a statistically significant consensus reduction in mortality (see Supplementary material online, Appendix S4).

Patients with ischaemic heart disease

This meta-analysis supports the current consensus that ICDs reduce all-cause mortality in left ventricular dysfunction with IHD, in the trials that use the current clinical convention of a dedicated device implant procedure. Interestingly, the reduction in hazard ratio is numerically the same (24%) in patients with and without IHD. Consequently, when considering ICD therapy, distinctions between the two groups may be unnecessary.

In acute myocardial infarction, however, there is no indication of a reduction in all-cause mortality.

Table 2 Risk of bias

Trial	CABG-Patch	MADIT I	MADIT II	CAT	AMIOVRT	DEFINITE	DINAMIT	COMPANION	SCD-HeFT	IRIS	DANISH
Year	1996	1996	2002	2002	2003	2004	2004	2004	2005	2009	2016
Author	Bigger	Moss	Moss	Bansch	Strickberger	Kadish	Hohnloser	Bristow	Brady	Steinbeck	Køber
Random sequence generation (selection bias)	Low risk	Unclear-not reported	Unclear-not reported	Low risk-central randomization	Unclear-not reported	Unclear-not reported	Low risk-central randomization with stratification	Unclear-not reported	Low risk	Low risk	Low risk-Web-based randomization with stratification
Allocation concealment (selection bias)	Unclear	Unclear-not reported	Unclear-not reported	Low risk-"closed envelopes with the assigned study group were sent to each centre ... envelopes were opened when a patient was enrolled"	Unclear-not reported	Unclear-not reported	Unclear-not reported	Unclear-not reported	Low risk	Unclear-not reported	Low risk
Blinding of participants and personnel (performance bias)	High-"nature of the intervention precluded the blinding of investigators or patients"	High risk	High risk	High risk	High risk	High risk	High risk	High risk-"patients, physicians ... were not blinded to the treatment assignments"	High risk	High risk	High risk
Blinding of outcome assessment (performance bias)	Unclear-"accumulating data were reviewed by an independent Data and Safety Monitoring Board", but no report of whether outcomes were blindly assessed	Unclear-"two member endpoint subcommittee reviewed information on the causes and circumstances of deaths", but no report on whether blinded	Unclear-not reported	Unclear-not reported	Low-"events committee determined the cause of death" ... "independently evaluated all information available" and "to assure a blinded review, all references to amiodarone or ICD therapy was removed from the reviewed documents"	Low-"cause of death was determined by an events committee ... un-	High-"ascertainment of the cause of death was the responsibility of the local investigators", but a "blinded central validation committee independently reviewed information on all deaths"	Low-"steering committee and endpoint committee were unaware of the treatment assignments"	Unclear-not reported	Low-"adverse-event committee that was unaware of the treatment assignments classified" the causes of death	Low-"endpoint classification committee, the members of which were unaware of the treatment assignments, used prespecified criteria to adjudicate all prespecified clinical outcomes"
Incomplete outcome data (attrition bias)	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
Selective reporting (reporting bias)	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
Other bias	Trial funded by CPI/Guidant who supplied devices, but had no role in design, analysis, interpretation or writing.	Trial funded by CPI/Guidant who supplied devices, but had no role in design, analysis, interpretation or writing.	Trial funded by CPI/Guidant who supplied devices, but had no role in design, analysis, interpretation or writing.	Trial funded by CPI/Guidant who supplied devices, but had no role in design, analysis, interpretation or writing.	Supported in part by an unrestricted research grant from the Guidant Corporation	Trial funded by St Jude who supplied devices, but had no role in design, analysis, interpretation or writing.	Trial funded by St Jude who supplied devices, but had no role in design, analysis, interpretation or writing.	Trial funded by Guidant who supplied devices, but had no role in design, analysis, interpretation or writing.	Trial funded by Medtronic who supplied devices, but had no role in design, analysis, interpretation or writing.	Trial funded by Medtronic who supplied devices and had access to the final pre-submission manuscript	Trial funded by Medtronic, St Jude, TrygFonden, but had no role in design, analysis, interpretation or writing.




Figure 2 Title: Left ventricular dysfunction without ischaemic heart disease: impact of primary prevention ICD on all-cause mortality.

Difference between this meta-analysis and previous meta-analyses

Our meta-analysis is the first to include the results of the patients without IHD from the COMPANION and DANISH trials. Other meta-analyses³³ have omitted COMPANION, presumably because the paper did not display the hazard ratio explicitly. However, the hazard ratio and its confidence interval can be calculated from the steps shown in Supplementary material online, Appendix S2. The current meta-analysis therefore provides important new information regarding the role of ICD therapy in patients with left ventricular dysfunction without IHD.

Study limitations

Any meta-analysis can only examine studies that have actually been carried out. Different studies took different approaches to recruitment. However, it is notable that all six non-ischaemic trial results were concordant not only in the direction of effect, but also the approximate magnitude, with the *I*² statistical test showing minor heterogeneity.

In the case of the COMPANION trial, the hazard ratio was calculated using the information published in the primary publication by steps shown in Supplementary material online, Appendix S2. The original publication did not comment on this hazard ratio. It is wise to be cautious of results of sub-group analyses, because many such analyses are possible and some will be positive by chance alone. However, the single most important dichotomy in current guidelines^{31,32} for primary prevention ICDs in left ventricular systolic dysfunction is the presence vs. absence of ischaemic heart disease. Therefore, this sub-group analysis need not be assumed to be a random result selected from many possible sub-groups analyses. Moreover, all six groups of patients without ischaemic heart disease showed the same direction

of effect. Furthermore, the finding is stable to the removal of any one trial (see Supplementary material online, Appendix S4).

Background medical therapy has improved over the time-course of these trials, with only 4% treated with beta-blockers in the CAT (2002), but 92% in DANISH (2016). Whilst the relative mortality-reduction effect size has remained remarkably consistent over time this will reduce the absolute effect size (when analysed over a fixed time window) of ICDs for primary prevention.

Our study could not consider the degree to which comorbidities might affect results. It has been noted that patients recruited into trials often have fewer comorbidities than those in the general population. The external validity of RCTs is always challenged by this, particularly in conditions such as heart failure where comorbidities may be frequent and severe.³⁴ Furthermore, whilst this meta-analysis finds that stratifying by the presence or absence of ischaemic heart disease does not influence the mortality benefit of ICDs in primary prevention, other factors might. Supplementary material online, Appendix S4 includes data stratified by the presence or absence of CRT, but this analysis is hindered by the limited data in CRT group which is derived from COMPANION⁶ and a sub-group of DANISH.²⁰ The 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy³⁵ similarly recognize that limited RCT data is available for the comparison between CRT-P and CRT-D. The guidelines suggest clinical conditions such as advanced or end-stage cardiac or renal disease may favour CRT-P over CRT-D.

Clinical implications

The challenge facing clinical trials, as highlighted by McMurray,³ is that skilful modern treatment algorithms have reduced event rates down to low levels in the types of patients who would be eligible for, and willing to enter, randomized controlled trials; the annualized rate is




Figure 3 (A) Title: Left ventricular dysfunction with ischaemic heart disease: impact of primary prevention ICD on all-cause mortality. (B). Title: Left ventricular dysfunction with ischaemic heart disease: impact of primary prevention ICD implanted during a dedicated procedure on all-cause mortality.




Figure 4 Left ventricular dysfunction with acute myocardial infarction: impact of primary prevention ICD on all-cause mortality.

5.4% in patients without IHD. In light of this perhaps, we should pay maximal attention to information that RCTs give us.

The low event rate in the trials is why viewing multiple trials is necessary to see the survival benefit. However, the 24% risk reduction is as sizable as one might realistically hope for, for any intervention. This meta-analysis provides strong support for the role of primary prevention ICDs in patients with left ventricular dysfunction. A 24% risk reduction in all-cause mortality is comparable with other therapies which we recommend in heart-failure such as candesartan³⁶ or an angiotensin-neprilysin inhibitor (HR 0.77, 0.84, respectively).³⁷

Conclusions

In patients with left ventricular dysfunction, primary prevention ICDs reduce mortality. ICDs reduce mortality by 24% in both patients with ($P = 0.03$) and without IHD ($P = 0.0023$).

When deciding on ICD therapy, classification of heart failure by aetiology may therefore not be useful.

Supplementary material

Supplementary material is available at *European Heart Journal* online.

Funding

This work was supported by the British Heart Foundation [grant numbers FS/14/27/30752 (MJSS), FS/12/12/29294 (GC), FS/13/44/30291 (ZW), FS/10/038 (DPF)].

Conflict of interest: M.J.S.S., S.Z., J.P.H., G.C., and D.P.F. declare no conflict of interest. ZW has received speaker fees from St. Jude, and a research grant unrelated to this work from Medtronic.

References

1. Betts TR, Sadarmin PP, Tomlinson DR, Rajappan K, Wong KCK, Bono JP. D. Bashir Y. Absolute risk reduction in total mortality with implantable cardioverter defibrillators: analysis of primary and secondary prevention trial data to aid risk/benefit analysis. *Europace* 2013;**15**:813–819.
2. Kusumoto FM, Calkins H, Boehmer J, Buxton AE, Chung MK, Gold MR, Hohnloser SH, Indik J, Lee R, Mehra MR, Menon V, Page RL, Shen W-K, Slotwimer DJ, Stevenson LW, Varosy PD, Welikovich L. HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials. *Circulation* 2014;**130**:94–125.
3. McMurray JJV. The ICD in heart failure—time for a rethink? *N Engl J Med* 2016;**375**:1283–1284.
4. Plot Digitizer [Internet]. Available from: <http://plotdigitizer.sourceforge.net/>. (24 January 2017).
5. Guyot P, Ades AE, Ouwens MJNM, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. *BMC Med Res Methodol* 2012;**12**:9.
6. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, Marco TD, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM. Comparison of medical therapy, pacing, and defibrillation in heart failure (COMPANION) investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. *N Engl J Med* 2004;**350**:2140–2150.
7. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. *Trials* 2007;**8**:16.
8. Strickberger SA, Hummel JD, Bartlett TG, Frumin HI, Schuger CD, Beau SL, Bitar C, Morady F. AMIOVIRT Investigators. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia—AMIOVIRT. *J Am Coll Cardiol* 2003;**41**:1707–1712.
9. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JAC. Cochrane Bias Methods Group, Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011;**343**:d5928.
10. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;**327**:557–560.
11. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;**315**:629–634.
12. R Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2016. Available from: <https://www.R-project.org/>. (24 January 2017).
13. Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. *Journal of Statistical Software* 2010;**36**:1–48.
14. Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;**6**:e1000097.
15. Bigger JT, Whang W, Rottman JN, Kleiger RE, Gottlieb CD, Namerow PB, Steinman RC, Estes NA. Mechanisms of death in the CABG Patch trial: a randomized trial of implantable cardiac defibrillator prophylaxis in patients at high risk of death after coronary artery bypass graft surgery. *Circulation* 1999;**99**:1416–1421.
16. Greenberg H, Case RB, Moss AJ, Brown MW, Carroll ER, Andrews ML. MADIT-II Investigators. Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II). *J Am Coll Cardiol* 2004;**43**:1459–1465.
17. Packer DL, Prutkin JM, Hellkamp AS, Mitchell LB, Bernstein RC, Wood F, Boehmer JP, Carlson MD, Frantz RP, McNulty SE, Rogers JG, Anderson J, Johnson GW, Walsh MN, Poole JE, Mark DB, Lee KL, Bardy GH. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. *Circulation* 2009;**120**:2170–2176.
18. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. *N Engl J Med* 2005;**352**:225–237.
19. Bänsch D, Antz M, Boczor S, Volkmer M, Tebbenjohanns J, Seidl K, Block M, Gietzen F, Berger J, Kuck KH. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). *Circulation* 2002;**105**:1453–1458.
20. Køber L, Thune JJ, Nielsen JC, Haarbø J, Videbæk L, Korup E, Jensen G, Hildebrandt P, Steffensen FH, Bruun NE, Eiskjær H, Brandes A, Thøgersen AM, Gustafsson F, Egstrup K, Videbæk R, Hassager C, Svendsen JH, Høfsten DE, Torp-Pedersen C, Pehrson S. DANISH Investigators. Defibrillator implantation in patients with nonischemic systolic heart failure. *N Engl J Med* 2016;**375**:1221–1230.
21. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NAM, Anderson KP, Calkins H, Hoch D, Goldberger J, Shalaby A, Sanders WE, Schaeckter A, Levine JH. Defibrillators in Non-Ischaemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. *N Engl J Med* 2004;**350**:2151–2158.
22. Bigger JT. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. *N Engl J Med* 1997;**337**:1569–1575.
23. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML. Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. *N Engl J Med* 2002;**346**:877–883.
24. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilber D, Brown MW, Heo M. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. *N Engl J Med* 1996;**335**:1933–1940.
25. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, Fain E, Gent M, Connolly SJ. DINAMIT Investigators. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. *N Engl J Med* 2004;**351**:2481–2488.
26. Steinbeck G, Andresen D, Seidl K, Brachmann J, Hoffmann E, Wojciechowski D, Kornacewicz-Jach Z, Sredniawa B, Lupkovic G, Hofgärtner F, Lubinski A, Rosenqvist M, Habets A, Wegscheider K, Senges J. IRIS Investigators. Defibrillator implantation early after myocardial infarction. *N Engl J Med* 2009;**361**:1427–1436.
27. Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, Mitchell LB, Green MS, Klein GJ, O'Brien B. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. *Circulation* 2000;**101**:1297–1302.
28. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The antiarrhythmics versus implantable defibrillators (AVID) investigators. *N Engl J Med* 1997;**337**:1576–1583.
29. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). *Circulation* 2000;**102**:748–754.
30. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. *N Engl J Med* 1999;**341**:1882–1890.
31. Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck K-H, Hernandez-Madrid A, Nikolaou N, Norekvål TM, Spaulding C, Veldhuisen DJ, Van. Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European society of cardiology (ESC)

- Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). *Eurpace* 2015;**17**:1601–1687.
32. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola V-P, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, Meer P, van der. Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 2016;**37**:2129–2200.
 33. Colquitt JL, Mendes D, Clegg AJ, Harris P, Cooper K, Picot J, Bryant J. Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure: systematic review and economic evaluation. *Health Technol Assess* 2014;**18**:1–560.
 34. Boriani G, Berti E, Belotti LMB, Biffi M, Palma R, De Malavasi VL, Bottoni N, Rossi L, Maria E, De Mantovan R, Zardini M, Casali E, Marconi M, Bandini A, Tomasi C, Boggian G, Barbato G, Toselli T, Zennaro M, Sassone B. RERAL (Registry of Emilia Romagna on Arrhythmia Interventions) Investigators. Cardiac device therapy in patients with left ventricular dysfunction and heart failure: “real-world” data on long-term outcomes (mortality, hospitalizations, days alive and out of hospital). *Eur J Heart Fail* 2016;**18**:693–702.
 35. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt O-A, Cleland J, Deharo J-C, Delgado V, Elliott PM, Gorennek B, Israel CW, Leclercq C, Linde C, Mont L, Padeletti L, Sutton R, Vardas PE. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). *Eur Heart J* 2013;**34**:2281–2329.
 36. Granger CB, McMurray JJV, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K. Charm Investigators Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. *The Lancet* 2003;**362**:772–776.
 37. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl J Med* 2014;**371**:993–1004.